Home/Pipeline/Lead Zytokine Program

Lead Zytokine Program

Solid Tumors

IND Approved / Phase 1 PlannedActive

Key Facts

Indication

Solid Tumors

Phase

IND Approved / Phase 1 Planned

Status

Active

Company

Trutino Biosciences

About Trutino Biosciences

Trutino Biosciences is a private, preclinical biotech leveraging its On-Demand-Cytokine (ODC) platform to engineer targeted cytokine prodrugs (Zytokines) for cancer and autoimmune disorders. The company has achieved a significant milestone with FDA IND approval for its lead program and is the subject of an option-to-acquire agreement with Boehringer Ingelheim. With a lean team and a focus on initiating its first Phase I study in solid tumors by Q1 2025, Trutino is positioned at a critical inflection point, aiming to demonstrate the clinical potential of its localized cytokine activation approach.

View full company profile

Therapeutic Areas

Oncology Autoimmune Diseases

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed